Veradermics to Participate in Upcoming March Investor Conferences

Veradermics (NYSE: MANE) announced management will attend two investor conferences in Miami in March.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/03/2026 - 07:00 AM EST

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March:

Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL
Reid Waldman, M.D., CEO of Veradermics, will participate in a fireside chat at 4:20 p.m. ET.

Jefferies Biotech on the Beach Summit on Wednesday, March 11 in Miami, FL

A live webcast of the Leerink conference fireside chat will be available on the “Events” page of the “Investors” section of the Company’s website at ir.veradermics.com. A replay of the webcast will be available for approximately 30 days following the event.

About Veradermics, Inc.
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, with potential selective development of medical dermatology product candidates. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss, to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform pattern hair loss treatment. VDPHL01 is an oral, extended-release proprietary formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. For additional information, visit www.veradermics.com and follow us on LinkedIn and Instagram.